

CV Date	03/03/2025
---------	------------

## Part A. PERSONAL INFORMATION

First Name *	Pedro		
Family Name *	Pérez Segura		
Sex *	Male	Date of Birth *	25/01/1968
ID number Social Security, Passport *		Phone Number *	(34) 913303546
URL Web			
Email Address	perezsegura09@gmail.com		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0001-5049-7199	
	Researcher ID		
	Scopus Author ID	https://scholar.google.com/citations?user=VR1cnBoA	

\* Mandatory

### A.1. Current position

Job Title	Head of Service		
Starting date	2017		
Institution	SERMAS		
Department / Centre			
Country		Phone Number	
Keywords			

### A.3. Education

Degree/Master/PhD	University / Country	Year
Senior Management of Health Services and Business Management	University of Alcalá	2004
Official Doctorate in Medicine Program	Complutense University of Madrid	1997
Graduate in medicine and surgery	Complutense University of Madrid	1992

### A.4. General quality indicators of scientific production

Total number of citations: 3076. H-Index: 24

## Part C. RELEVANT ACCOMPLISHMENTS

### C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 Scientific paper.** Francisco Javier Candel; Pablo Barreiro; Miguel Salavert; et al; José Luis Piñana; (6/20) Pedro Pérez Segura. 2023. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2. Viruses. <https://doi.org/10.3390/v15071449>
- 2 Scientific paper.** Elena González Guerra; Alberto Conde Taboada; José Antonio Cortés Toro; Eduardo López Bran; (5/5) Pedro Pérez Segura. 2023. Dermatologists might be the first to suspect hereditary leiomyomatosis and renal cell carcinoma syndrome. An Bras Dermatol. 98, pp.696-698.
- 3 Scientific paper.** Jordi Rubió Casadevall; Beatriz Cirauqui Cirauqui; Javier Martínez Trufero; et al; Ricard Mesia; (8/20) Pedro Pérez Segura. 2023. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol. <https://doi.org/10.3389/fonc.2023.1226939>

- 4 **Scientific paper.** Cristina Nieto Jiménez; Adrián Sanvicente; Cristina Díaz Tejeiro; et al; Alberto Ocaña; (8/9) Pedro Pérez Segura. 2023. Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates. Clin Transl Med. <https://doi.org/10.1002/ctm2.1329>
- 5 **Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barberán; Javier David Benítez Fuentes; et al; (14/14) Pedro Pérez Segura. 2023. Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck. <https://doi.org/10.3390/cancers15092431>
- 6 **Scientific paper.** Lucía Paniagua Herranz; Bernard Doger; Cristina Díaz Tejeiro; et al; Alberto Ocaña; (7/10) Pedro Pérez Segura. 2023. Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities. Cancers. <https://doi.org/10.3390/cancers15123250>
- 7 **Scientific paper.** Jesús Fuentes Antrás; Ana Martínez Rodríguez; Kissy Guevara Hoyer; et al; José Ángel García Sáenz; (13/18) Pedro Pérez Segura. 2023. Real-World use of highly sensitive liquid biopsy monitoring in metastatic breast cancer patients treated with endocrine agents after exposure to aromatase inhibitors. Int J Mol Sci. <https://doi.org/10.3390/ijms241411419>
- 8 **Scientific paper.** (1/10) Pedro Pérez Segura; Noelia Vilariño Quintela; María Martínez García; et al; Estela Pineda Losada. 2023. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood. Clin Transl Oncol. <https://doi.org/10.1007/s12094-023-03245-y>.
- 9 **Scientific-technical report.** Carmen Baeto Zambrano; (2/10) Pedro Pérez Segura; Sergio Vázquez Estevez; et al; Ana Santaballa Bertrán. 2023. Estudio de necesidades para establecer un Servicio de teleoncología. Glosa. ISBN 978-84-09-48507-9.
- 10 Yolanda Escobar; Avinash Ramchandani; Mercedes Salgado; et al; Paula Jiménez Fonseca; (10/19) Pedro Pérez Segura. 2023. What do patients and oncologists think about the evaluation and management of cancer related anorexia cachexia? The Quasar\_ SEOM study. Clin Transl Oncol. <https://doi.org/10.1007/s12094-023-03212-7>

## C.2. Conferences and meetings

- 1 Análisis de los eventos tromboembólicos venosos en pacientes con cáncer colorrectal: datos del registro TESEO-SEOM. X Congreso SEOM. 2023.
- 2 Análisis retrospectivo del uso de catéteres centrales de inserción periférica (PICC) en el servicio de oncología médica de un hospital terciario de España. X Congreso SEOM. 2023.
- 3 Análisis retrospectivo del uso de catéteres centrales de inserción periférica (PICC) en el servicio de oncología médica de un hospital terciario de España. X Congreso SEOM. 2023.
- 4 Eficacia y seguridad de la quimioterapia de rescate tras la progresión a agentes anti-pd(l)1 en pacientes con cáncer de cabeza y cuello recurrente/metastásico influencia de los esquemas de quimioterapia previos a nivolumab en la supervivencia de los pacientes con carcinoma escamoso de cabeza y cuello recurrentes y/o metastásicos (cecrr/m). análisis retrospectivo observacional de un centro. X Congreso SEOM. 2023.
- 5 Estudio descriptivo de enfermedad tromboembólica en pacientes con cáncer de mama en el registro TESEO. X Congreso SEOM. 2023.
- 6 Estudio descriptivo de enfermedad tromboembólica en pacientes con cáncer de mama en el registro TESEO. X Congreso SEOM. 2023.

## C.3. Research projects and contracts

- 1 **Project.** Study of the mutational status of IDH and immunoregulatory gene expression in circulating tumor DNA and correlation with the primary tumor in patients with gliomas.. Spanish Neuro-oncology Research Group. (San Carlos Clinical Hospital). 29/11/2016-29/11/2018. 30.000 €. collaborator.
- 2 **Project.** Identification of molecular markers predictive of cancer development in premalignant laryngeal lesions and contribution to the process of carcinogenesis in head and neck cancer.. Spanish Association Against Cancer. (San Carlos Clinical Hospital). 02/11/2015-02/11/2018. collaborator.
- 3 **Project.** Evaluation of the efficacy of 18 FDG PET-CT in the early diagnosis of breast and/or ovarian cancer in women carrying BRCA1 and 2 gene mutations.. (Mutua Madrileña Foundation for Medical Research). 01/01/2007-01/01/2010. Principal investigator.

- 4 **Project.** Identification and characterization of tumor stem cell subpopulation in human brain gliomas: relationship with neural stem cells.. (Mutua Madrileña Foundation for Medical Research). 01/01/2007-01/01/2010. collaborator.
- 5 **Project.** Utility of proteomic analysis as a molecular marker of breast cancer risk in women carrying BRCA gene mutations.. (Santiago Dexeus Font Foundation). 01/01/2006-01/01/2007. Principal investigator.
- 6 **Project.** Cost-effectiveness analysis of the follow-up of a BRCA1/2 gene mutation carrier population.. (Francisco de Vitoria Institute of Economic and Social Research). 01/01/2005-01/01/2007. Principal investigator.
- 7 **Project.** Study of genetic instability in breast cancer and mutations in BRCA1 and BRCA2 genes: diagnostic and prognostic evaluation.. (Carlos III Health Institute). 01/01/2004-01/01/2007. collaborator.
- 8 **Project.** Unclassified variants in BRCA1 and BRCA2: risk of breast cancer. (Autonomous Community of Madrid). 01/01/2003-01/01/2005. collaborator.
- 9 **Project.** Identification of low penetrance genes in familial and sporadic breast cancer patients. (Carlos III Health Institute). 01/01/2001-01/01/2004. collaborator.
- 10 **Project.** Study of BRCA1 and BRCA2 expression in hereditary and sporadic breast cancer: relationship with other clinical molecular variables.. (Autonomous community of madrid). 01/01/2001-01/01/2003. collaborator.
- 11 **Contract.** Randomized phase III trial of MK-3475 (Pembrolizumab) versus conventional treatment in subjects with recurrent or metastatic head and neck cancer. Code: MK-3475-040 Principal Investigator. From 27/03/2015.
- 12 **Contract.** Phase IIB, randomized, multicenter, multicenter, clinical trial of continuation or non-continuation with temozolomide cycles after the first 6 cycles of standard first-line treatment in patients with glioblastoma. Code: GEINO-14-01. Principal Investigator. From 01/03/2015.
- 13 **Contract.** Prospective, observational study to evaluate the benefit/risk of vandetanib(CAPRELSA TM) 300 mg in patients with symptomatic, aggressive, sporadic, locally advanced or metastatic, unresectable medullary thyroid cancer (MTC) with or without RET mutation Code: D4200C00104 / CAPRELSA From 17/02/2015.
- 14 **Contract.** Phase II, 2-stage, 2-cohort study evaluating BMN673 in patients with locally advanced and/or metastatic breast cancer who have germline mutations in BRCA genes. Code: 673-201/ARM From 10/02/2015.
- 15 **Contract.** Multicenter, open-label, three-period, fixed-sequence, Phase I study to investigate the effect of vemurafenib on the pharmacokinetics of a single dose of acenocoumarol in patients with metastatic malignancy with BRAFV600 mutation Code: GO28397 Principal Investigator. From 12/02/2014.
- 16 **Contract.** Phase IIIb, randomized, placebo-comparative, double-blind, double-blind study evaluating the efficacy and safety of treatment as usual (TAU) +/- maintained treatment with bevacizumab after disease progression (PE) in patients with glioblastoma (GGBM) following first-line treatment with radiotherapy, temozolamide and bevacizumab. Code: MO29347/TAMIGA Principal Investigator. From 01/10/2013.
- 17 **Contract.** Open-label, multicenter, expanded access study with RAD001 for patients with angiomyolipomas associated with tuberous sclerosis complex. Code: CRAD001MES12. Principal Investigator. From 01/05/2013.
- 18 **Contract.** Phase II trial of a sequential regimen of induction chemotherapy with panitumumab and paclitaxel followed by radiotherapy plus panitumumumab in patients with locally advanced head and neck cancer who are not candidates for platinum-derivative therapy. PANTERA/ TTCC 2010-06. Principal Investigator. From 01/04/2013.
- 19 **Contract.** Prospective, multicenter study of NovoTTF-100A together with temozolamide compared to temozolamide alone in patients with newly diagnosed glioblastoma multiforme. Code: EF-14 Principal Investigator. From 01/12/2012.
- 20 **Contract.** Characterization of genetic variants involved in the susceptibility to the development of head and neck squamous cell carcinomas in the Spanish population, response to treatment and toxicity. Clinical correlation. Code: TTCC-2010-05 From 01/05/2012.

#### **C.4. Activities of technology / knowledge transfer and results exploitation**

23382324.4. Genetic signature for predicting a subject's response to immunotherapies Spain. 18/08/2023.

#### **C.5. Stays in public or private R&D centres**

Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering Cancer Center. United States of America. New York. 01/04/2001-30/06/2001. 3 months. Post-doctoral.